Therapeutics News

ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Henry W. Lim, MD, FAAD, discusses highlights from the meeting.

ORLANDO, Fla. – The American Academy of Dermatology announced it has installed a new vice president and board members, who will take office at the end of its annual meeting.

ORLANDO, Fla. – Henry W. Lim, MD, FAAD, chair emeritus of the department of dermatology and senior vice president for Academic Affairs at Henry Ford Health System in Detroit, took office as president of the American Academy of Dermatology at its annual meeting.

ORLANDO – Healio.com/Dermatology is providing live coverage of the 75th annual American Academy of Dermatology Annual Meeting in Orlando beginning today.

Data from a phase 2b trial examining the safety and efficacy of the therapeutic vaccine GEN-003 for the treatment of genital herpes showed that three doses of treatment reduced the rate of genital lesions as well as the number and duration of recurrences 6 months after administration compared with placebo, according to a press release.

Research funding that psoriasis had a strong association with type 2 diabetes and obesity in a nationwide study of Danish twins was among the 10 most-read articles of 2016 on Healio.com/Dermatology.

The National Psoriasis Foundation announced in a press release it has awarded more than $1.9 million in research in 2016, including 23 projects around the world.

In Europe, the Committee for Medicinal Products for Human Use has recommended approval for Ilaris in patients with tumor necrosis factor-receptor associated periodic syndrome, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency or familial Mediterranean fever, according to a press release.

WASHINGTON — At the American College of Rheumatology Annual Meeting, Dinesh Khanna, MD, rheumatologist and director of the scleroderma program at the University of Michigan, reviewed open-label extension data from the fasscinate trial. The trial was a phase 2 randomized controlled study of subcutaneous tocilizumab for patients with early systemic sclerosis (SSc) that was extended an additional 48 weeks from the initial 48-week period.

The American Society for Dermatologic Surgery Association recognized physicians with Patient Safety Hero and Federal Advocate awards at the ASDS annual meeting in New Orleans.